FIG. 6.

MitoTEMPO does not alter the adaptive immune response. C57Bl/6J mice were treated once daily via intranasal administration of MitoTEMPO (100 μg) over a 6-day period 1 day before virus infections. Mice were intranasally infected with X31 (10³ PFUs) or PBS control. Single cells were isolated from whole lung digests, and multidimensional flow cytometry was used to quantify the relative abundance of (A) DCs, (B) B cells, and (C) T cells. DCs are measured as CD11b⁺ CD11c⁺ cells gated from the F4/80 negative population. T and B cell populations are measured as a percentage of CD3⁺ and CD19⁺ cells, respectively, gated from the CD45⁺ population. Data are expressed as mean ± SEM (Control, n = 8; MitoTEMPO, n = 8; X31 n = 12 X31+mito n = 12). Statistical analysis was conducted using one-way ANOVA test followed by Tukey's post hoc test for multiple comparisons. Statistical significance was taken where p < 0.05 (**p < 0.01). DCs, dendritic cells.